Developmental Pipeline

Pipeline

Drug Candidate

Trial Design

Indication

Pre-clinical

Phase 1

Phase 2

Phase 3

Oral
Cannabidiol
Formulation

Evaluate the efficacy and safety of CardiolRx in patients with COVID-19 and Cardiovascular Disease or Risk Factors. A double-blind , placebo-controlled trial

Reduce Cardiorespiratory complications in hospitalized COVID-19 Patients
more

close

Evaluate the efficacy and safety of CardiolRx in Patients with COVID-19 and Cardiovascular Disease or Risk Factors

CardiolRx™

Cardiol has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application to conduct a Phase II/III clinical trial investigating the efficacy and safety of CardiolRx in the treatment of hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease. Learn more…

Oral
Cannabidiol
Formulation

Impact of CardiolRx on Myocardial Recovery in acute myocarditis. A double-blind, placebo-controlled trial

Acute Myocarditis
more

close

Impact of CardiolRx on Myocardial Recovery in acute myocarditis

CardiolRx™

Cardiol has completed a Phase I safety and pharmacokinetic study of CardiolRx and is planning an international, multi-center Phase II study to investigate the therapeutic effects of CardiolRx on myocardial recovery in patients with acute myocarditis, a leading cause of sudden cardiac death in people under 35 years of age. Learn more…

Oral
Cannabidiol
Formulation

Evaluate the tolerance and safety of CardiolRX in patients with recurrent pericarditis - an Open-label Pilot Study

Recurrent Pericarditis
more

close

Evaluate the tolerance and safety of CardiolRX in patients with recurrent pericarditis

CardiolRx™

Subcutaneous
Cannabidiol
Forumlation

For the treatment of fibrosis and inflammation in the heart associated with the development & progression of diastolic heart failure (HFpEF)

Heart Failure
more

close

For the treatment of fibrosis and inflammation in the heart associated with the development & progression of diastolic heart failure (HFpEF)

CardiolRx™

The Company is also developing a subcutaneous formulation of CardiolRx to achieve higher bioavailability for the treatment of chronic heart failure.  Heart failure affects over six million people in North America and remains a leading cause of death and hospitalization with associated U.S. healthcare costs exceeding $30 billion annually. Learn more…